FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder
Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021
Read Moreby Lucy Parsons | Jun 2, 2021 | News | 0
Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021
Read Moreby Anna Smith | Feb 4, 2019 | News | 0
The US Food and Drug Administration (FDA) has rejected Alkermes’ filing for ALKS 5461 in major depressive disorder (MDD), asking for more clinical data.
Read Moreby Anna Smith | Dec 18, 2018 | News | 0
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for experimental multiple sclerosis (MS) drug diroximel fumarate.
Read Moreby Selina McKee | Nov 2, 2018 | News | 0
Alkermes’ ALKS 5461 has been hit with a potential setback in the US after regulatory advisors failed to back its approval for major depressive disorder (MDD).
Read Moreby Selina McKee | Nov 29, 2017 | News | 0
Dublin, Ireland-based Alkermes has licensed ALKS 8700, a novel, oral, small drug molecule in Phase III development for relapsing forms of multiple sclerosis, to US biotech Biogen.
Read Moreby Selina McKee | Oct 21, 2016 | News | 0
Shares in Ireland-headquartered Alkermes shot up nearly 50 percent after its experimental depression drug hit targets in a pivotal late-stage trial.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
